BioXcel Therapeutics, Inc. (BTAI)
Automate Your Wheel Strategy on BTAI
With Tiblio's Option Bot, you can configure your own wheel strategy including BTAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BTAI
- Rev/Share 0.0483
- Book/Share -2.3519
- PB -0.523
- Debt/Equity -1.1703
- CurrentRatio 1.4788
- ROIC -2.9532
- MktCap 7448942.0
- FreeCF/Share -1.7309
- PFCF -0.1122
- PE -1.1771
- Debt/Assets 2.7362
- DivYield 0
- ROE 0.4669
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $1.50 per share versus the Zacks Consensus Estimate of a loss of $2.72. This compares to loss of $13.92 per share a year ago.
Read More
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 intended to support potential sNDA submission for label expansion of IGALMI ® in the at-home setting Strengthened cash position to advance BXCL501 program NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported its financial results for the fourth quarter and full year 2024.
Read More
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale in a registered direct offering of 4,000,000 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”) (or common stock equivalents in lieu thereof), and accompanying warrants (the “Accompanying Warrants”) to purchase up to 4,000,000 shares of Common Stock at a combined offering price of $3.50 per Share (or …
Read More
BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
Read More
About BioXcel Therapeutics, Inc. (BTAI)
- IPO Date 2018-03-08
- Website https://www.bioxceltherapeutics.com
- Industry Biotechnology
- CEO Dr. Vimal D. Mehta Ph.D.
- Employees 37